Clinical trials of therapies for heart failure (HF) are usually performed in patients with left ventricular systolic dysfunction (LVSD) and reduced left ventricular ejection fraction (LVEF). The ...
Background There is a lack of contemporary data describing patients with left ventricular (LV) systolic dysfunction post ...
In the current issue of Cardiovascular Innovations and Applications (Volume3, Number 1, 2018, pp. pp. 21-30(10); DOI 10.15212/CVIA.2017.0050, Ali N. Zaidi and W. Aaron Kay from Columbus Ohio Adult ...
Because life expectancy and the prevalence of risk factors such as hypertension, obesity and diabetes are rising globally, heart failure (HF) is growing into a major health problem. Impairment of left ...
Please provide your email address to receive an email when new articles are posted on . ECGs analyzed by AI identified left ventricular systolic dysfunction in patients who presented to the ED with ...
The CHARM program consisted of 3 component trials that compared candesartan with placebo in patients with symptomatic heart failure. Two trials randomized patients with LVEF ≤ 40%: CHARM-Alternative, ...
Cardiomyopathy is the leading cause of mortality in patients with DMD. Compared with their healthy counterparts, patients with DMD — including those with preserved left ventricular ejection fraction ...
Credit: Getty Images Worsening renal function may be associated with left ventricular ejection fraction in patients with acute heart failure. Worsening renal function (WRF) may be associated with left ...
In the current issue of Cardiovascular Innovations and Applications (Volume3, Number 1, 2018, pp. pp. 21-30(10); DOI 10.15212/CVIA.2017.0050, Ali N. Zaidi and W. Aaron Kay from Columbus Ohio Adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results